Finance Watch: ADARx Raises $200m, Alltrna Garners $109m To Fund RNA Medicines

Kyverna Increased Series B By $60m To $145m

Private Company Edition: Recent venture capital mega-rounds of $100m or more include ADARx and Alltrna, which closed five days after CG Oncology brought in $105m. Also, Tisento launched with assets from Cyclerion and $81m in series A funding and Georgiamune raised a $75m series A round.

Finance Watch Private Company
• Source: Shutterstock

Two companies with different approaches to RNA medicines announced venture capital mega-rounds of $100m or more on 9 August – ADARx Pharmaceuticals, Inc. with a $200m series C financing and Alltrna with a $109m series B.

The month has had two other notable mega-round reveals, including a $105m crossover financing that CG Oncology, Inc. said it closed on 2 August. Kyverna Therapeutics also announced on 3 August that it closed a $60m series B extension, bringing the round’s total to $145m. These four financings may reestablish this year’s brisk mega-round pace, which slowed to just two $100m-plus VC rounds in July, including Kriya Therapeutics, Inc.’s $150m-plus series C extension

More from Financing

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By 

The sector is continuing to show resilience despite financial and market challenges.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By 

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

Finance Watch: Biohaven Gains Up To $600m In Fresh Capital

 
• By 

Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By 

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

More from Business